Privia Health Group Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
PRVA$24.37-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands except share amounts)
| Common Stock Shares | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Equity attributable to Privia Health Group, Inc. | Non-controlling Interest | Total Stockholders’ Equity | |
|---|---|---|---|---|---|---|---|
| Balance at January 1, 2021 | 95,985,817 | $960 | $165,666 | $(19,878) | $146,748 | $(3,096) | $143,652 |
| Issuance of common stock upon closing of initial public offering | 9,725,000 | 97 | 210,897 | — | 210,994 | — | 210,994 |
| Issuance of common stock upon exercise of stock options and vesting of restricted stock units | 2,126,924 | 21 | 3,808 | — | 3,829 | — | 3,829 |
| Stock-based compensation expense | — | — | 253,531 | — | 253,531 | — | 253,531 |
| Contributed non-controlling interest | — | — | — | — | — | 28,824 | 28,824 |
| Net loss | — | — | — | (188,230) | (188,230) | (2,419) | (190,649) |
| Balance at Balance at December 31, 2021 | 107,837,741 | 1,078 | 633,902 | (208,108) | 426,872 | 23,309 | 450,181 |
| Issuance of common stock upon exercise of stock options and vesting of restricted stock units | 6,853,067 | 70 | 13,378 | — | 13,448 | — | 13,448 |
| Stock-based compensation expense | — | — | 67,359 | — | 67,359 | — | 67,359 |
| Contributed non-controlling interest | — | — | — | — | — | 125 | 125 |
| Net loss | — | — | — | (8,585) | (8,585) | (3,479) | (12,064) |
| Balance at December 31, 2022 | 114,690,808 | 1,148 | 714,639 | (216,693) | 499,094 | 19,955 | 519,049 |
| Issuance of common stock upon exercise of stock options and vesting of restricted stock units | 3,526,171 | 34 | 8,706 | — | 8,740 | — | 8,740 |
| Stock-based compensation expense | — | — | 37,098 | — | 37,098 | — | 37,098 |
| Repurchase of non-controlling interest | — | — | (8,871) | — | (8,871) | 3,177 | (5,694) |
| Contributed non-controlling interest | — | — | — | — | — | 24,871 | 24,871 |
| Tax effect related to purchase of non-controlling interest | — | — | 2,297 | — | 2,297 | — | 2,297 |
| Net income (loss) | — | — | — | 23,079 | 23,079 | (2,051) | 21,028 |
| Balance at December 31, 2023 | 118,216,979 | $1,182 | $753,869 | $(193,614) | $561,437 | $45,952 | $607,389 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.